文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.

作者信息

Hoiland Ryan L, Stukas Sophie, Cooper Jennifer, Thiara Sonny, Chen Luke Y C, Biggs Catherine M, Hay Kevin, Lee Agnes Y Y, Shojania Kamran, Abdulla Alym, Wellington Cheryl L, Sekhon Mypinder S

机构信息

Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

Centre for Heart, Lung, and Vascular Health, School of Health and Exercise Sciences, University of British Columbia - Okanagan, Kelowna, BC, Canada.

出版信息

Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.

DOI:10.1111/bjh.16961
PMID:32584416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7361645/
Abstract
摘要

相似文献

[1]
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.

Br J Haematol. 2020-8

[2]
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.

Br J Haematol. 2020-8

[3]
The COVID-19 Cytokine Storm; What We Know So Far.

Front Immunol. 2020-6-16

[4]
Cytokine Storm Drugs Move from CAR T to COVID-19.

Cancer Discov. 2020-5-5

[5]
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.

Mult Scler Relat Disord. 2020-6

[6]
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.

Eur Respir J. 2020-10-1

[7]
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.

In Vivo. 2020-6

[8]
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.

J Clin Immunol. 2020-10

[9]
Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.

Kidney Int. 2020-8

[10]
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.

Int Immunopharmacol. 2020-7-1

引用本文的文献

[1]
Network Pharmacology and Experiment Verification-Based Strategy for Exploring the Mechanisms of Shuqing Granule in the Treatment of COVID-19.

Pharmaceuticals (Basel). 2025-8-18

[2]
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.

PLoS One. 2025-4-2

[3]
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.

BMC Infect Dis. 2024-8-9

[4]
A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.

Adv Ther (Weinh). 2022-10

[5]
Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer.

ACS Appl Mater Interfaces. 2022-11-2

[6]
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.

Lancet Reg Health Am. 2022-7

[7]
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.

Inflammopharmacology. 2022-2

[8]
Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Front Immunol. 2021

[9]
Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?

Regen Med. 2021-5

[10]
Absence of "Cytokine Storm" in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.

Infect Dis Rep. 2021-4-19

本文引用的文献

[1]
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.

Blood Rev. 2021-1

[2]
Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.

Ann Intern Med. 2020-9-15

[3]
Effective treatment of severe COVID-19 patients with tocilizumab.

Proc Natl Acad Sci U S A. 2020-4-29

[4]
Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.

Intensive Care Med. 2020-6

[5]
Elevated interleukin-6 and severe COVID-19: A meta-analysis.

J Med Virol. 2020-11

[6]
Clinical and immunological features of severe and moderate coronavirus disease 2019.

J Clin Invest. 2020-5-1

[7]
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

BMJ. 2020-3-26

[8]
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.

Clin Infect Dis. 2020-7-28

[9]
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Lancet. 2020-3-11

[10]
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.

Clin Infect Dis. 2020-7-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索